Market Access Views & Analysis

Views & Analysis

Market Access

Navigating new risks: How China’s Anti-Espionage Law could i...

The pharmaceutical industry is facing another challenge as China seems to strengthen its Anti-Espionage Law, which introduces uncertainties that could disrupt the global supply of essential

Market Access

Metrics for the UK’s VPAG: A work in progress

Just as for previous schemes, metrics are being used to track VPAG, the UK’s voluntary scheme that covers branded medicines pricing and access.

Market Access

Progress with the UK’s VPAG

Leela Barham looks at the first operational review meeting minutes that have been published on the VPAG, the UK’s latest scheme on branded medicines pricing and access, building on previous

Market Access

Updating of England’s budget impact test threshold

England has a lot of ways to put downward pressure on prices of new treatments and the budget impact test - prompting commercial discussions if a new treatment looks like it will cost more

Market Access